{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:36:30Z","timestamp":1774895790765,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to assess the efficacy of concurrent magnesium-sodium valproate therapy and compare it with either magnesium or sodium valproate alone in migraine prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This randomized single-center double-blind parallel-group controlled clinical trial study was conducted on migraine patients within the age range of 18\u201365\u2009years. The subjects with at least four monthly attacks were randomly assigned to group A (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200982) sodium valproate, group B (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200970) magnesium with sodium valproate, and group C (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200970) magnesium. The patients passed a one-month baseline without prophylactic therapy and then received a 3-month treatment. The characteristics of migraine, including frequency, severity, duration of the attacks, and the number of painkillers taken per month, were monthly recorded in each visit. The Migraine Disability Assessment (MIDAS) and Headache Impact Test-6 (HIT-6) scores were recorded at the baseline and after 3\u2009months of treatment in each group. Within- and between-group analyses were performed in this study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The obtained results revealed a significant reduction in all migraine characteristics in all groups compared to those reported for the baseline (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.001). Intragroup data analysis indicated that there was no statistically significant difference in headache frequency between groups A and B in the third month (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.525); nevertheless, three other parameters showed a significant reduction in group B, compared to those reported for group A in the third month (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.05). On the other hand, group C could not effectively reduce measured parameters in the patients, compared to groups A and B after 3 months (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.001). Furthermore, the MIDAS and HIT-6 scores significantly diminished in groups A, B, and C compared to those reported at the baseline (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.001), and these changes were more significant in groups A and B than in group C (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The obtained results of this study revealed that magnesium could enhance the antimigraine properties of sodium valproate in combination therapy and reduce the required valproate dose for migraine prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-021-01234-6","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T09:06:05Z","timestamp":1617786365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Samira","family":"Khani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Amir","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Yaghoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5793-3288","authenticated-orcid":false,"given":"Ehsan","family":"Sharifipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"3","key":"1234_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0304-3940(80)90168-8","volume":"20","author":"BT Altura","year":"1980","unstructured":"Altura BT, Altura BM (1980) Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries. Neurosci Lett 20(3):323\u2013327","journal-title":"Neurosci Lett"},{"key":"1234_CR2","doi-asserted-by":"crossref","unstructured":"Assarzadegan, F., H. Tabesh, S.-M. Hosseini-Zijoud, A. D. Beale, A. Shoghli, M. G. Yazdi, B. Mansouri, O. Hesami, N. B. Moghadam and H. D. J. I. R. C. M. J. Kasmaei (2016). \"Comparing zonisamide with sodium valproate in the management of migraine headaches: double-blind randomized clinical trial of efficacy and safety.\" 18(9)","DOI":"10.5812\/ircmj.23768"},{"key":"1234_CR3","doi-asserted-by":"crossref","unstructured":"Bigal, M. E., A. M. Rapoport, R. B. Lipton, S. J. Tepper, F. D. J. H. T. J. o. H. Sheftell and F. Pain (2003). \"Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine.\" 43(4): 336\u2013342","DOI":"10.1046\/j.1526-4610.2003.03068.x"},{"key":"1234_CR4","doi-asserted-by":"crossref","unstructured":"Bostani, A., A. Rajabi, N. Moradian, N. Razazian and M. J. I. J. o. N. Rezaei (2013). \"The effects of cinnarizine versus sodium valproate in migraine prophylaxis.\" 123(7): 487\u2013493","DOI":"10.3109\/00207454.2013.765419"},{"key":"1234_CR5","doi-asserted-by":"crossref","unstructured":"Canger, R. and L. J. C. D. I. Guidolin (2000). \"Clinical Efficacy and Tolerability of Magnesium Valproate as Monotherapy in Patients with Generalised or Partial Epilepsy.\" 20(4): 215\u2013221","DOI":"10.2165\/00044011-200020040-00002"},{"key":"1234_CR6","doi-asserted-by":"crossref","unstructured":"Cutrer, F., V. Limmroth and M. J. C. Moskowitz (1997). \"Possible mechanisms of valproate in migraine prophylaxis.\" 17(2): 93\u2013100","DOI":"10.1046\/j.1468-2982.1997.1702093.x"},{"key":"1234_CR7","unstructured":"Dalla Volta, G. J. I. J. N. B. D. (2017). \"Combi-nation of Tanacethum Partenium, 5-Hy-drossitriptophan (5-Http) and Magnesium in the Prophylaxis of Episodic Migraine without Aura (AURASTOP\u00ae)-An Obser-vational Study.(2017) Int J Neuro Brain Dis 4 (3): 1\u20134.\" 4(3)"},{"key":"1234_CR8","doi-asserted-by":"crossref","unstructured":"Daniel, O. and A. J. C. t. o. i. n. Mauskop (2016). \"Nutraceuticals in acute and prophylactic treatment of migraine.\" 18(4): 14","DOI":"10.1007\/s11940-016-0398-1"},{"key":"1234_CR9","doi-asserted-by":"crossref","unstructured":"Dolati, S., R. Rikhtegar, A. Mehdizadeh and M. J. B. t. e. r. Yousefi (2019). \"The Role of Magnesium in Pathophysiology and Migraine Treatment.\" 1\u20139","DOI":"10.1007\/s12011-019-01931-z"},{"key":"1234_CR10","doi-asserted-by":"crossref","unstructured":"Facchinetti, F., G. Sances, P. Borella, A. R. Genazzani, G. J. H. T. J. o. H. Nappi and F. Pain (1991). \"Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium.\" 31(5): 298\u2013301","DOI":"10.1111\/j.1526-4610.1991.hed3105298.x"},{"key":"1234_CR11","doi-asserted-by":"crossref","unstructured":"Farhadi, Z., S. Alidoost, M. Behzadifar, R. Mohammadibakhsh, N. Khodadadi, R. Sepehrian, R. Sohrabi, M. T. Mirghaed, M. Salemi and H. J. I. R. C. M. J. Ravaghi (2016). \"The prevalence of migraine in Iran: A systematic review and meta-analysis.\" 18(10)","DOI":"10.5812\/ircmj.40061"},{"key":"1234_CR12","unstructured":"Faryadi, Q. J. I. J. o. A. (2012). \"The magnificent effect of magnesium to human health: a critical review.\" 2(3)"},{"key":"1234_CR13","doi-asserted-by":"crossref","unstructured":"Fueta, Y., A. Siniscalchi, V. Tancredi and M. J. E. Avoli (1995). \"Extracellular magnesium and anticonvulsant effects of valproate in young rat hippocampus.\" 36(4): 404\u2013409","DOI":"10.1111\/j.1528-1157.1995.tb01016.x"},{"key":"1234_CR14","unstructured":"Giorgio Dalla, V., P. Zavarize, G. Ngonga, A. Pezzini, G. J. I. J. o. N. Dalla Volta and B. Disorders (2017). \"Combination of Tanacethum Partenium, 5-Hydrossitriptophan (5-Http) and Magnesium in the Prophylaxis of Episodic Migraine without Aura (AURASTOP\u00c2\u00ae) An Observational Study.\" 4(1): 0\u20130"},{"key":"1234_CR15","unstructured":"Ha, H. and A. J. A. f. p. Gonzalez (2019). \"Migraine Headache Prophylaxis.\" 99(1)"},{"key":"1234_CR16","unstructured":"Hesami, O., M. R. Shams, L. Ayazkhoo, F. Assarzadegan, B. S. Lima, H. D. Kasmaei and M. J. I. j. o. p. r. I. Sistanizad (2018). \"Comparison of pregabalin and sodium valproate in migraine prophylaxis: a randomized double-blinded study.\" 17(2): 783"},{"issue":"2","key":"1234_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13311-018-0616-5","volume":"15","author":"J Hoffmann","year":"2018","unstructured":"Hoffmann J, Charles A (2018) Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 15(2):361\u2013370. https:\/\/doi.org\/10.1007\/s13311-018-0616-5","journal-title":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"},{"key":"1234_CR18","doi-asserted-by":"crossref","unstructured":"Holla, R., B. Darshan, Y. Z. Ying, T. Raymond, E. Ponniah, K. S. San, N. Y. J. I. J. o. P. H. R. Yen and Development (2019). \"Clinical Characteristics and Associated Disability of Headache among Medical Undergraduates.\" 10(8): 647\u2013650","DOI":"10.5958\/0976-5506.2019.01960.0"},{"key":"1234_CR19","doi-asserted-by":"crossref","unstructured":"Homam, M., A. Farajpour, S. Khadem and Z. J. C. J. o. N. S. Mostafavian (2016). \"The experiential comparison of levetiracetam efficacy in migraine headache with sodium valproate.\" 2(2): 42\u201349","DOI":"10.18869\/acadpub.cjns.2.5.42"},{"key":"1234_CR20","doi-asserted-by":"crossref","unstructured":"Ichikawa, M., H. Katoh, T. Kurihara and M. J. J. o. C. N. Ishii (2016). \"Clinical response to valproate in patients with migraine.\" 12(4): 468\u2013475","DOI":"10.3988\/jcn.2016.12.4.468"},{"key":"1234_CR21","doi-asserted-by":"crossref","unstructured":"Karimi, N., A. Razian and M. J. A. N. B. Heidari (2019). \"The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study.\" 1\u20137","DOI":"10.1007\/s13760-019-01101-x"},{"key":"1234_CR22","unstructured":"Keyvan, G. and M.-B. J. P. j. o. b. s. P. Abolfazl (2009). \"Comparison of treatment effect of sodium valproate, propranolol and tricyclic antidepressants in migraine.\" 12(15): 1098\u20131101"},{"key":"1234_CR23","unstructured":"K\u00f6seoglu, E., A. Talasl\u0131oglu, A. S. G\u00f6n\u00fcl and M. J. M. r. Kula (2008). \"The effects of magnesium prophylaxis in migraine without aura.\" 21(2): 101\u2013108"},{"key":"1234_CR24","doi-asserted-by":"crossref","unstructured":"Lingam, I. and N. J. J. D. n. Robertson (2018). \"Magnesium as a neuroprotective agent: a review of its use in the fetus, term infant with neonatal encephalopathy, and the adult stroke patient.\" 40(1): 1\u201312","DOI":"10.1159\/000484891"},{"key":"1234_CR25","doi-asserted-by":"crossref","unstructured":"Maier, J. A., G. Pickering, E. Giacomoni, A. Cazzaniga and P. J. N. Pellegrino (2020). \"Headaches and Magnesium: Mechanisms, Bioavailability, Therapeutic Efficacy and Potential Advantage of Magnesium Pidolate.\" 12(9): 2660","DOI":"10.3390\/nu12092660"},{"key":"1234_CR26","doi-asserted-by":"crossref","unstructured":"Mathew, N. T., J. R. Saper, S. D. Silberstein, L. Rankin, H. G. Markley, S. Solomon, A. M. Rapoport, C. J. Silber and R. L. J. A. o. N. Deaton (1995). \"Migraine prophylaxis with divalproex.\" 52(3): 281\u2013286","DOI":"10.1001\/archneur.1995.00540270077022"},{"key":"1234_CR27","doi-asserted-by":"crossref","unstructured":"Parikh, S. K. and S. D. J. C. t. o. i. n. Silberstein (2019). \"Current Status of Antiepileptic Drugs as Preventive Migraine Therapy.\" 21(4): 16","DOI":"10.1007\/s11940-019-0558-1"},{"key":"1234_CR28","unstructured":"Pringsheim, T., W. Davenport, G. Mackie, I. Worthington, M. Aub\u00e9, S. N. Christie, J. Gladstone and W. J. J. C. J. N. S. Becker (2012). \"Canadian Headache Society guideline for migraine prophylaxis.\" 39(2 Suppl 2): S1\u201359"},{"issue":"2","key":"1234_CR29","first-page":"274","volume":"38","author":"M Romoli","year":"2018","unstructured":"Romoli M, Costa C, Siliquini S, Corbelli I, Eusebi P, Bedetti C, Caproni S, Cupini LM, Calabresi P, Sarchielli PJC (2018) Antiepileptic drugs in migraine and epilepsy. Who is at increased risk of adverse events? 38(2):274\u2013282","journal-title":"Who is at increased risk of adverse events?"},{"key":"1234_CR30","doi-asserted-by":"crossref","unstructured":"Rondon, L., A. Privat, L. Daulhac, N. Davin, A. Mazur, J. Fialip, A. Eschalier and C. J. T. J. o. p. Courteix (2010). \"Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain.\" 588(21): 4205\u20134215","DOI":"10.1113\/jphysiol.2010.197004"},{"key":"1234_CR31","doi-asserted-by":"crossref","unstructured":"Safar, M. M., D. M. Abdallah, N. M. Arafa and M. T. J. B. r. Abdel-Aziz (2010). \"Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats.\" 1334: 58\u201364","DOI":"10.1016\/j.brainres.2010.03.076"},{"key":"1234_CR32","doi-asserted-by":"crossref","unstructured":"Shahien, R. and K. J. J. o. c. n. s. d. Beiruti (2012). \"Preventive agents for migraine: focus on the antiepileptic drugs.\" 4: JCNSD. S9049","DOI":"10.4137\/JCNSD.S9049"},{"key":"1234_CR33","doi-asserted-by":"crossref","unstructured":"Shaygannejad, V., M. Janghorbani, A. Ghorbani, F. Ashtary, N. Zakizade, V. J. H. T. J. o. H. Nasr and F. Pain (2006). \"Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study.\" 46(4): 642\u2013648","DOI":"10.1111\/j.1526-4610.2006.00413.x"},{"key":"1234_CR34","doi-asserted-by":"crossref","unstructured":"Shin, H. E., J. W. Park, Y. I. Kim and K. S. J. J. o. c. n. Lee (2008). \"Headache Impact Test-6 (HIT-6) scores for migraine patients: Their relation to disability as measured from a headache diary.\" 4(4): 158\u2013163","DOI":"10.3988\/jcn.2008.4.4.158"},{"key":"1234_CR35","doi-asserted-by":"crossref","unstructured":"Skljarevski, V., M. Matharu, B. A. Millen, M. H. Ossipov, B.-K. Kim and J. Y. J. C. Yang (2018). \"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial.\" 38(8): 1442\u20131454","DOI":"10.1177\/0333102418779543"},{"key":"1234_CR36","doi-asserted-by":"crossref","unstructured":"Slavin, M., H. Li, M. Khatri, C. J. H. T. J. o. H. Frankenfeld and F. Pain (2021). \"Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001\u20132004.\"","DOI":"10.1111\/head.14065"},{"key":"1234_CR37","unstructured":"Spasi\u0107, M., M. \u017divkovi\u0107 and S. J. M. B. Luki\u0107 (2003). \"Prophylactic treatment of migraine by valproate.\" 10(3): 106\u2013110"},{"key":"1234_CR38","doi-asserted-by":"crossref","unstructured":"Sprenger, T., M. Viana and C. J. N. Tassorelli (2018). \"Current prophylactic medications for migraine and their potential mechanisms of action.\" 15(2): 313\u2013323","DOI":"10.1007\/s13311-018-0621-8"},{"key":"1234_CR39","doi-asserted-by":"crossref","unstructured":"Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ (2011) The global campaign, world health organization and lifting the burden: collaboration in action. BioMed Central","DOI":"10.1007\/s10194-011-0342-4"},{"key":"1234_CR40","unstructured":"Taubert, K. J. F. d. M. (1994). \"Magnesium in migraine. Results of a multicenter pilot study.\" 112(24): 328\u2013330"},{"key":"1234_CR41","doi-asserted-by":"crossref","unstructured":"Von Luckner, A., F. J. H. T. J. o. H. Riederer and F. Pain (2018). \"Magnesium in migraine prophylaxis\u2014is there an evidence-based rationale? A systematic review.\" 58(2): 199\u2013209","DOI":"10.1111\/head.13217"},{"key":"1234_CR42","doi-asserted-by":"crossref","unstructured":"Vuckovic, S., D. Srebro, K. Savic Vujovic and M. J. P. b. Prostran (2015). \"The antinociceptive effects of magnesium sulfate and MK-801 in visceral inflammatory pain model: the role of NO\/cGMP\/K+ ATP pathway.\" 53(11): 1621-1627","DOI":"10.3109\/13880209.2014.996821"},{"key":"1234_CR43","doi-asserted-by":"crossref","unstructured":"Waldrop, M. A. and S. J. J. C. t. o. i. n. Kolb (2019). \"Current Treatment Options in Neurology\u2014SMA Therapeutics.\" 21(6): 25","DOI":"10.1007\/s11940-019-0568-z"},{"key":"1234_CR44","doi-asserted-by":"crossref","unstructured":"Weatherall, M. W. J. T. a. i. c. d. (2015). \"The diagnosis and treatment of chronic migraine.\" 6(3): 115\u2013123","DOI":"10.1177\/2040622315579627"},{"key":"1234_CR45","doi-asserted-by":"crossref","unstructured":"Weglicki, W. B., T. M. J. A. J. o. P.-R. Phillips, Integrative and C. Physiology (1992). \"Pathobiology of magnesium deficiency: a cytokine\/neurogenic inflammation hypothesis.\" 263(3): R734-R737","DOI":"10.1152\/ajpregu.1992.263.3.R734"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01234-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-021-01234-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01234-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T04:21:47Z","timestamp":1619842907000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01234-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01234-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-152651\/v1","asserted-by":"object"}]},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"15 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Ethics Committee of Qom University of Medical Sciences in Qom, Iran (special approval ID: IR.MUQ.REC.1394.73) on August 26 in 2015 in accordance with the Helsinki Declaration. Also, written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"We give our consent for the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Non","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}